person · Reporting owner
DIGIANDOMENICO ANTHONY
Disclosed activity across 7 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearSign Technologies CorpCLIR · Entity 7487 | Director | September 30, 2026 | October 02, 2026 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | December 24, 2018 | January 04, 2019 |
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Director | January 21, 2026 | January 24, 2026 |
| EXOZYMES INC.IZTC · Entity 1147 | Director · 10% owner | November 08, 2024 | November 19, 2024 |
| Illumination Acquisition Corp. IILLU · Entity 5913 | Director | February 26, 2026 | February 26, 2026 |
| MDB Capital Holdings, LLCMDBH · Entity 7469 | Director · 10% owner | April 28, 2025 | August 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearSign Technologies Corp
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Statutory Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2036-09-29 | Direct | 3,766 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 3,766 · Balance 3,766 F1: As compensation for services as a non-employee director during the quarter ended September 30, 2026, the reporting person was granted non-statutory stock options to purchase 3,766 shares of common stock under the ClearSign Technologies Corporation Amended and Restated 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: As compensation for services as a non-employee director during the quarter ended September 30, 2026, the reporting person was granted non-statutory stock options to purchase 3,766 shares of common stock under the ClearSign Technologies Corporation Amended and Restated 2021 Equity Incentive Plan pursuant to the issuer's non-employee director compensation policy. These non-statutory stock options were immediately vested and exercisable on the grant date.
Cue Biopharma, Inc.
Report date December 24, 2018 · Filed January 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2018-12-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-12-24 · Purchase · Acquired 10,000 · Balance 30,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.94, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: Shares are held jointly with the reporting person's spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.94, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4
F2: Shares are held jointly with the reporting person's spouse.
ENDRA Life Sciences Inc.
Report date January 21, 2026 · Filed January 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,589 |
Reported balance
After 2026-01-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 60,324 · Balance 136,589 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.
F2: Includes unvested RSUs.
EXOZYMES INC.
Report date November 08, 2024 · Filed November 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,808,476 |
Reported balance
Holding disclosure · report date 2024-11-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,808,476 F1: Shares are held by MDB Capital Holdings, LLC, over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC. |
| SAFE for Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2024-11-30 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2024-11-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The SAFE converts into Common Stock upon the closing of a public offering of IZTC's securities. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC. F1: Shares are held by MDB Capital Holdings, LLC, over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC. |
| Warrant for Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2025-06-22 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2024-11-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The warrant is held by MDB Capital Holdings, LLC and is exercisable at $2.44, until June 22, 2025. The Reporting Person disclaims any interest in the shares underlying the warrant except to the extent of his pecuniary interest in MDB Capital Holdings, LLC. F1: Shares are held by MDB Capital Holdings, LLC, over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC. |
| Stock Options for Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2028-01-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-11-08 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The shares underlying the grant vest at the rate of 1,299 shares each quarter and are fully vested on January 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by MDB Capital Holdings, LLC, over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC.
F2: The SAFE converts into Common Stock upon the closing of a public offering of IZTC's securities. The Reporting Person disclaims any interest in the shares except to the extent of his pecuniary interests in MDB Capital Holdings, LLC.
F3: The warrant is held by MDB Capital Holdings, LLC and is exercisable at $2.44, until June 22, 2025. The Reporting Person disclaims any interest in the shares underlying the warrant except to the extent of his pecuniary interest in MDB Capital Holdings, LLC.
F4: The shares underlying the grant vest at the rate of 1,299 shares each quarter and are fully vested on January 31, 2026.
Illumination Acquisition Corp. I
Report date February 26, 2026 · Filed February 26, 2026
This filing explicitly reported no securities owned.
MDB Capital Holdings, LLC
Report date April 28, 2025 · Filed August 08, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2025-04-28 | Direct | 0 |
Reported balance
After 2025-04-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-04-28 · Disposition to issuer · Disposed 900,000 · Balance 0 |
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2035-04-28 | Direct | 900,000 |
Reported balance
After 2025-04-28 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2025-04-28 · Grant · Acquired 900,000 · Balance 900,000 F1: 400,000 Class A Shares will vest as follows: 200,000 shares vest immediately on grant and the remainder vest in 22 equal monthly installments of 8,333 shares for each complete subsequent month of Continuous Service (as defined in the 2022 Equity Performance Plan) and 8,341 will vest on March 15, 2027. F2: 500,000 Class A Shares are performance-based and vest upon the date on which either of the following occurs during the Exercisability Period (as defined in the Plan and option agreement: (x) a Class A Share has traded in the market on which the Class A Shares are listed for at least thirty (30) trading days at an average price of $20.00 or more, whether consecutive or non-consecutive, or (y) there are distributions of cash, stock or other property by the Company on the Class A Shares, at a value of $20.00 or more in the aggregate per Class A Share. |
Filing footnotes · ownership attribution and instrument terms
F1: 400,000 Class A Shares will vest as follows: 200,000 shares vest immediately on grant and the remainder vest in 22 equal monthly installments of 8,333 shares for each complete subsequent month of Continuous Service (as defined in the 2022 Equity Performance Plan) and 8,341 will vest on March 15, 2027.
F2: 500,000 Class A Shares are performance-based and vest upon the date on which either of the following occurs during the Exercisability Period (as defined in the Plan and option agreement: (x) a Class A Share has traded in the market on which the Class A Shares are listed for at least thirty (30) trading days at an average price of $20.00 or more, whether consecutive or non-consecutive, or (y) there are distributions of cash, stock or other property by the Company on the Class A Shares, at a value of $20.00 or more in the aggregate per Class A Share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Provention Bio, Inc.
Report date May 15, 2020 · Filed June 17, 2020
Section 16 reporting ended · disclosed 2020-06-17. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2020 Filed Jul 23, 2020 12:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | OtherCommon Stock | 100,503 | $0.87 | $87,437.61 |
DisclosureSEC source: 0001209191-20-043430 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,012 F1 · balance_after: Included unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 11:27 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 5,000 | $0.92 | $4,600.00 |
DisclosureSEC source: 0001209191-20-035185 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 28, 2020 Filed May 29, 2020 10:49 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 5,000 | $0.90 | $4,500.00 |
DisclosureSEC source: 0001209191-20-032827 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.88 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: The balance reflects an adjustment to correct a computational error in column 5 of the reporting person's Form 4 filed December 11, 2019, which stated 199,226 but should have stated 218,652. Read SEC document |
| May 22, 2020 Filed May 26, 2020 11:03 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.78 | $7,800.00 |
DisclosureSEC source: 0001209191-20-031895 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,083 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.74 to $0.81, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:42 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024215 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,083 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:19 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001778 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:48 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantWarrants · Derivative | 100,503 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060084 · doc4.xml · derivative · entry 3 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,503 Underlying: Common Stock · 100,503 shares Expires 2024-12-11 F2 · price: The Warrants were issued for no additional consideration in connection with the purchase of the common stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:48 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock option (right to buy) · Derivative | 89,585 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060084 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,585 Underlying: Common Stock · 89,585 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:48 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 100,503 | $0.87 | $87,437.61 |
DisclosureSEC source: 0001209191-19-060084 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,226 Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 22:26 UTC | Provention Bio, Inc. PRVB · Entity 12101 | OtherCommon Stock | 342,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-018862 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,712 F1 · kind: Pro rata distribution from MDB Capital Group LLC, of which the reporting person is a minority owner. Read SEC document |
| September 30, 2019 Filed Sep 30, 2019 21:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 30,000 | $6.83 | $204,900.00 |
DisclosureSEC source: 0001493152-19-014772 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.83 to $6.85, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 26, 2019 Filed Sep 26, 2019 22:08 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 5,000 | $8.44 | $42,200.00 |
DisclosureSEC source: 0001493152-19-014640 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.30 to $8.78, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 25, 2019 Filed Sep 25, 2019 21:45 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 5,000 | $8.39 | $41,950.00 |
DisclosureSEC source: 0001493152-19-014570 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.36 to $8.41, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 10:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $9.09 | $90,900.00 |
DisclosureSEC source: 0001493152-19-011940 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.96 to $9.18, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001493152-19-009704 · ownership.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock, par value $0.0001 · 24,000 shares Expires 2029-06-24 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The option fully vests on May 28, 2020. Read SEC document |
| June 20, 2019 Filed Jun 20, 2019 21:37 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $10.96 | $109,600.00 |
DisclosureSEC source: 0001493152-19-009515 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.82 to $11.09, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 01:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $10.88 | $108,800.00 |
DisclosureSEC source: 0001493152-19-009410 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.84 to $10.89, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 17, 2019 Filed Jun 17, 2019 22:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 25,000 | $12.16 | $304,000.00 |
DisclosureSEC source: 0001493152-19-009336 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.77 to $12.72, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:06 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-19-021518 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-25 F1 · shares: Represents a stock option award granted on March 25, 2019 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 25, 2020. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:36 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001321 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| December 28, 2018 Filed Dec 31, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001493152-18-018149 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.73 to $1.81, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 21:18 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 7,000 | $4.62 | $32,340.00 |
DisclosureSEC source: 0001209191-19-000261 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.56 to $4.70, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 20,000 | $1.95 | $39,000.00 |
DisclosureSEC source: 0001493152-18-018087 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $2.13, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 13:40 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 20,000 | $4.77 | $95,400.00 |
DisclosureSEC source: 0001209191-18-064233 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.63 to $4.93, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 24, 2018 Filed Dec 27, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 17,270 | $1.92 | $33,158.40 |
DisclosureSEC source: 0001493152-18-018017 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.82 to $1.99, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 24, 2018 Filed Jan 4, 2019 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 10,000 | $4.81 | $48,100.00 |
DisclosureSEC source: 0001209191-19-002244 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.94, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 2,000 | $1.85 | $3,700.00 |
DisclosureSEC source: 0001493152-18-017965 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,442 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.76 to $1.89, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 21:07 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 10,000 | $4.49 | $44,900.00 |
DisclosureSEC source: 0001209191-18-064085 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.34 to $4.66, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 5,000 | $1.96 | $9,800.00 |
DisclosureSEC source: 0001493152-18-017874 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,442 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $1.99, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 21:31 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 10,000 | $5.48 | $54,800.00 |
DisclosureSEC source: 0001209191-18-063198 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.34 to $5.57, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 4,442 | $2.45 | $10,882.90 |
DisclosureSEC source: 0001493152-18-017143 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,442 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.23 to $2.58, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 00:13 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 4,849 | $2.45 | $11,880.05 |
DisclosureSEC source: 0001493152-18-016978 · ownership.xml · nonDerivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.49, inclusive. Read SEC document |
| November 29, 2018 Filed Dec 4, 2018 00:13 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 151 | $2.47 | $372.97 |
DisclosureSEC source: 0001493152-18-016978 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,151 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.48, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 23:11 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $2.46 | $24,600.00 |
DisclosureSEC source: 0001493152-18-016826 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.38 to $2.54, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 23:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $2.65 | $26,500.00 |
DisclosureSEC source: 0001493152-18-016761 · ownership.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.73, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 21:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $100,000.00 Strike: $1.68 | $100,000.00 |
DisclosureSEC source: 0001209191-18-058718 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 59,524 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Pursuant to the terms of the Convertible Promissory Note (the "Note"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 21:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionCommon Stock | 59,524 | $1.68 | $100,000.32 |
DisclosureSEC source: 0001209191-18-058718 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2). Read SEC document |
| July 19, 2018 Filed Jul 19, 2018 21:54 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 128,981 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001493152-18-010230 · ownership.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Underlying: Common Stock, par value $0.0001 · 128,981 shares Expires 2028-07-19 F2 · price: The securities were granted pursuant to the Issuer's 2017 Equity Incentive Plan, effective as of the closing of the Issuer's initial public offering of common stock. F1 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on January 19, 2018 and will become fully vested on July 19, 2022. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 23:39 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantWarrants · Derivative | 24,802 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-18-040510 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,802 Underlying: Common Stock · 24,802 shares Expires 2021-06-28 F4 · price: The Warrants were issued for no additional consideration in connection with the offer and sale of the Note. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 23:39 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantConvertible Promissory Note · Derivative | Not disclosed | $100,000.00 | $100,000.00 |
DisclosureSEC source: 0001209191-18-040510 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 49,604 shares Expires 2018-12-31 F1 · derivative.exercise_price: The Convertible Promissory Note (the "Note") is convertible into the Issuer's common stock at a conversion price equal to the lesser of (a) the lowest per share price at which common stock is sold by the Issuer in a sale resulting in aggregate gross cash proceeds of at least $7.0 million (a "Qualified Financing"), less a discount of 20%, or (b) $2.016, but in any event no less than a conversion price floor of $1.40, which conversion price is subject to adjustment in certain circumstances in accordance with the terms of the Note. F2 · derivative.exercise_date: The principal amount of the Note will automatically convert into shares of the Issuer's common stock (i) upon the consummation of a Qualified Financing or (ii) if the holders of a majority of the aggregate principal amount of outstanding Convertible Promissory Notes elect to convert such notes at any time until three days prior to a Qualified Financing. Additionally, the reporting person is entitled to convert the principal amount of the Note into common stock (i) at any time until three days prior to the consummation of a Qualified Financing or (ii) if a material Event of Default (as defined in the Note) shall have occurred and be continuing. In each case, conversion is subject to the terms and provisions of the Note. F3 · derivative.underlying_shares: The number of shares of common stock shown in Column 7 assumes a conversion price of $2.016, which is subject to adjustment in certain circumstances (see Footnote 1). Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:31 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037810 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:22 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,061 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001654954-18-000107 · section16.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,061 Underlying: Common Stock · 6,061 shares Expires 2026-01-02 F1 · shares: Represents a stock option award granted on January 2, 2018 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 12, 2017 Filed May 19, 2017 20:07 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033918 · doc4.xml · derivative · entry 3 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2022-05-12 Read SEC document |
| May 12, 2017 Filed May 19, 2017 20:07 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $1.40 | $27,196.00 |
DisclosureSEC source: 0001209191-17-033918 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The principal amount of, and accrued interest on, the Convertible Promissory Note converted into shares of Common Stock of the Issuer at a conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| May 12, 2017 Filed May 19, 2017 20:07 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionCommon Stock | 19,426 | $1.40 | $27,196.40 |
DisclosureSEC source: 0001209191-17-033918 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note, as described in footnote (2). Read SEC document |
| May 12, 2017 Filed May 23, 2017 22:11 UTC Amendment | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034740 · doc4a.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-12 F2 · derivative.exercise_date: This amendment is being filed to correct the exercisable date of these Stock Options, which was inadvertantly reported as May 12, 2017. The correct exercisable date is December 31, 2017. F1 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025. Read SEC document |
| May 12, 2017 Filed May 23, 2017 22:11 UTC Amendment | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034740 · doc4a.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-12 F1 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.